ArticlePloS one2015
Precore/Core Region Mutations in Hepatitis B Virus DNA Predict Postoperative Survival in Hepatocellular Carcinoma.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Precore/core mutation relatedness to viral reactivation in patients undergoing targeted therapy for hepatitis B virus-related hepatocellular carcinoma.World journal of biological chemistry · 2026Review
- Hepatitis B Virus Genomic Variability & HBV-Related Disease Outcomes: A Molecular Epidemiology Perspective.Journal of medical virology · 2025Article
- HBV precore G1896A mutation promotes growth of hepatocellular carcinoma cells by activating ERK/MAPK pathway.Virologica Sinica · 2023Article
- Perioperative predictors of outcome of hepatectomy for HBV-related hepatocellular carcinoma.Frontiers in oncology · 2023Review
- Review on hepatitis B virus precore/core promoter mutations and their correlation with genotypes and liver disease severity.World journal of hepatology · 2022Review
- Article
- Article
- HBV mutations in EnhII/BCP/PC region contribute to the prognosis of hepatocellular carcinoma.Cancer medicine · 2019Article
- CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis.BioMed research international · 2019Article
- The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease.Frontiers in cellular and infection microbiology · 2018Article
- The mutation of hepatitis B virus and the prognosis of hepatocellular carcinoma after surgery: a pilot study.Cancer management and research · 2018Article
- The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.Molecular cancer · 2017Review
- Detection and molecular characterisation of a diagnosis escape variant associated with occult hepatitis B virus in Brazil.Memorias do Instituto Oswaldo Cruz · 2017Article
- Hepatitis B virus core antigen mutations predict post-operative prognosis of patients with primary hepatocellular carcinoma.The Journal of general virology · 2017Article
- Mutations in hepatitis B virus polymerase are associated with the postoperative survival of hepatocellular carcinoma patients.PloS one · 2017Article
- HBV core promoter mutations and AKT upregulate S-phase kinase-associated protein 2 to promote postoperative hepatocellular carcinoma progression.Scientific reports · 2016Article
- Precore/core region mutations of hepatitis B virus related to clinical severity.World journal of gastroenterology · 2016Review
- Mutations in hepatitis B virus smallOncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) DNA is prone to mutations because of the proofreading deficiencies of HBV polymerase. We have identified hepatocellular carcinoma (HCC) survival-associated HBV mutations in the X protein region of HBV DNA. In the present study, we extend our research to assess HCC survival-associated HBV mutations in the HBV precore/core (PreC/C) region. The PreC/C region was amplified and sequenced and the HBV mutations were identified according to the NCBI database (http://www.ncbi.nlm.nih.gov/genome/5536). The relationships between the mutations in the PreC/C region and HCC survival were analyzed. Survival curves were generated using the Kaplan-Meier method, and comparisons between the curves were made using the log-rank test. Multivariate survival analysis was performed using a Cox proportional hazards model. After adjusting for clinical characteristics, the 1915, 2134, 2221, 2245 and 2288 mutational sites were identified as statistically significant independent predictors of HCC survival by multivariate survival analysis using a Cox proportional hazards model. In addition, the mutational site of 1896 was identified for its association with survival at a borderline significance level. A total of five mutations in the precore/core region were identified as independent predictors of postoperative survival in HCC patients. The analysis of HBV DNA mutations may help identify patient subgroups with poor prognosis and may help refine therapeutic decisions regarding HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.